2025 年，中国内窥镜 / 手术机器人行业在国产替代深化、技术创新加速与全球市场拓展的多重驱动下，成为医 疗科技领域的 "融资高地"。头部企业凭借技术突破与商业化潜力吸引全球资本关注，中小型创新企业则聚焦细分 赛道实现差异化融资，全年融资活动呈现"高端化、全球化、细分化"等特征。 从融资情况来看， 2025 年，国产内窥镜企业融资规模与质量同步提升，据不完全统计，全年公开融资事件超 15 起，融资总额突破 50 亿元，其中单笔融资超 10 亿元的案例 3 起，超 2 亿美元的大额融资 1 起，资本关注 度较 2024 年提升 35% 。 4K/ 荧光 /3D 成像 / AI 成热点：内窥镜与手术机器人结合是趋势 整体看来， 2025 年融资企业的技术布局，集中体现了国产内窥镜行业"突破高端、补齐短板、整合创新"的发展 逻辑。无论是头部企业的"机器人 + 内镜"协同，还是细分企业的"一次性 + 专科"聚焦，均以"临床需求"为核 心，在成像精度、极端环境适应性、智能化水平三大维度实现突破，逐步缩小与国际巨头的技术代际差。 2025 年 1 月，微创外科供应链平台企业杭州鑫泽源医疗科技有限公司（下称"鑫泽源"） ...

Core Viewpoint - Agile Medical has completed a multi-hundred million RMB Series B financing round, aimed at global commercialization, product development, and technology platform upgrades [3]. Group 1: Product Development and Clinical Application - The core product AGIBOT® laparoscopic surgical robot is expected to be approved for market launch by March 2025, with over 100 complex surgical applications already completed in top-tier hospitals [3]. - The AGIBOT® features an integrated suspension design and a dual-guidance system combining laser and camera visualization, reducing average docking time to under 3 minutes [3]. - The robot enhances operational flexibility and precision, providing over 96 liters of effective operational space for surgeons during complex laparoscopic procedures [4]. Group 2: Innovation and Data Utilization - Agile Medical emphasizes clinical needs in product development, integrating frontline feedback into the R&D process to address challenges in medical-engineering integration [3][4]. - The increasing clinical cases of the laparoscopic surgical robot allow the intelligent platform to collect more surgical data, which can be analyzed using artificial intelligence for further product optimization [4]. Group 3: Commercialization and Supply Chain - Cost control and supply chain management are critical for the laparoscopic surgical robot's competitiveness in both domestic and international markets [5]. - Agile Medical has adopted a fully self-researched core technology path and established a research and production base in Suzhou, capable of producing 100 systems and 20,000 surgical instruments annually [5]. - The company plans to enhance capabilities in force feedback and AI, aiming for smarter surgical robots, while also initiating overseas certification and engaging with potential clinical partners in international markets [5].

Core Insights - Agile Medical Technology (Suzhou) Co., Ltd. has recently completed a multi-hundred million RMB Series B financing round, led by Mingxi Capital, with participation from Yuanhe Holdings, Licheng Investment, and Nantong Investment Management, along with continued investment from existing shareholders Qianji Capital and Yuanhe Origin [1][2] Group 1: Financing and Investment - The funds from this financing round will be primarily used for three key areas: deepening global commercialization efforts, accelerating the research and development iteration of surgical robot product lines, and further upgrading cutting-edge technology platforms [1] Group 2: Company Background and Product Development - Founded in 2020, Agile focuses on the surgical robot industry and has completed multiple rounds of financing prior to this [2] - The core product, AGIBOT® laparoscopic surgical robot, is expected to receive approval from the National Medical Products Administration (NMPA) by March 2025 and has already been applied in over a hundred clinical cases at leading institutions such as Nanjing University Medical School Affiliated Gulou Hospital and Zhengzhou University First Affiliated Hospital [2] - Agile has established a comprehensive capability loop from research and development to market, with a production base and user training center in Suzhou, capable of producing 100 systems and 20,000 surgical instruments annually, supporting professional user training for hundreds of individuals each year [2] - The company continues to strengthen its capabilities in technology research, pipeline development, industrial operations, and commercial expansion, forming a complete system covering "R&D - certification - mass production - commercialization" [2]

Core Insights - Agile Medical Technology (Suzhou) Co., Ltd. has completed a multi-hundred million RMB Series B financing round, led by Mingxi Capital, with participation from Yuanhe Holdings, Licheng Investment, and Nantong Investment Management, along with continued investment from existing shareholders [1][2] - The funds will be primarily used for three key areas: deepening global commercialization, accelerating the R&D iteration of surgical robot product lines, and further upgrading cutting-edge technology platforms [1] Company Developments - The core product, AGIBOT® laparoscopic surgical robot, is expected to receive approval from the National Medical Products Administration (NMPA) by March 2025, and has already completed over 100 clinical applications in top-tier hospitals [1] - Agile Medical has established a comprehensive capability loop from R&D to market, with a production base in Suzhou capable of manufacturing 100 systems and 20,000 surgical instruments annually, along with professional user training for hundreds of individuals each year [1] Innovation and Market Position - As an innovator in China's surgical robot industry, Agile Medical focuses on user needs and continues to build a technological foundation based on "AGI+BOT" through independent innovation [2] - The recent financing round reaffirms the capital market's confidence in the company's development path of "innovative technology + inclusive healthcare" [2]

Core Insights - Agile Medical recently completed a Series B financing round of several hundred million RMB, led by Mingxi Capital, with participation from Yuanhe Holdings, Licheng Investment, and Nantong Investment Management, along with existing investors Qianji Capital and Yuanhe Origin [1] - The funding will primarily be used for global commercialization expansion, iterative development of surgical robot products, and upgrades to advanced technology platforms [1] Group 1 - The core product AGIBOT® laparoscopic surgical robot received market approval in March 2025 and has completed over a hundred complex clinical applications in top-tier hospitals [1] - The AGIBOT® robot features an integrated suspension design and a dual-guidance system combining laser and camera visualization, reducing average docking time to under 3 minutes [1][2] - The surgical platform includes a force-sensing module and dual-motor drive, allowing healthcare personnel to maneuver the cart with one hand, enhancing flexibility in crowded operating rooms [1] Group 2 - The development of surgical robots is guided by clinical needs, but challenges exist in the integration of medical and engineering practices [1] - The robot's design enhances the flexibility and control precision of instruments during complex laparoscopic surgeries, providing over 96 liters of effective operational space [2] - Agile Medical has established a research and production base in Suzhou, capable of producing 100 systems and 20,000 surgical instruments annually, focusing on cost control and supply chain management for competitive advantage [2] Group 3 - The company aims to enhance capabilities in force feedback and artificial intelligence to improve the robot's perception and decision-making abilities, facilitating intelligent upgrades [2] - Agile Medical has initiated overseas certification processes and is engaging with potential clinical partners in various international markets to prepare for global expansion [2]